President Trump said the U.S. Navy would build a new ‘Trump-class’ battleship, with construction of the first ship to begin almost immediately. Photo: Alex Brandon/Associated Press President Trump ...

Korean biopharmaceutical company Adel announced Monday that it has secured a license-out agreement worth up to $1.04 billion with multinational health care firm Sanofi for the development and ...

Adel (ADEL), which is jointly developing an Alzheimer's disease drug candidate with Oscotec, said on the 16th that it signed a technology transfer agreement with French drugmaker Sanofi to transfer ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

ADEL Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases, has entered into an exclusive worldwide license agreement with Sanofi, a multinational ...

Deal includes $80 million upfront payment, with total potential value up to $1.04 billion plus royalties ADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. The French pharma is paying ...

Dec 16 (Reuters) - South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with ‌French drugmaker Sanofi to develop and sell the ‌biotech company's experimental ...